Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

Articles

Nonalcoholic Steatohepatitis Treatment Market: ...

Non-alcoholic fatty liver disease is one of the most common causes of liver disease in the United States. As per the National Institute of Diabetes and Digestive and Kidney Diseases, only a small n...

Dec 19, 2022

Bispecific Antibodies in DLBCL, Opportunities and Challenges
ASH 2022- Emergence of Bispecific antibodies in DLBCL: Prospects, Opportunities, and Challenges

The American Society of Hematology (ASH) Annual Meeting this year presented abstracts showcasing new data from across its bispecific antibodies clinical pipeline, demonstrating the companies’ commitment to redefining care for patients with DLBCL.  Recently, off-the-shelf bispecific antibodies have grow...

Find More
Top Abstracts In the Follicular Lymphoma (FL) Therapeutics Market at the ASH 2022
ASH 2022: Preview of the Top Abstracts In the Follicular Lymphoma (FL) Therapeutics Market

American Society of Hematology (ASH) presented fresh abstracts from a strong portfolio and pipeline of cutting-edge treatment platforms for cancer and blood diseases, underscoring the significance of our audacious science in research. Delveinsight has provided a summary of some of the key abstracts and their result...

Find More
Roche’s Polivy vs ADC Therapeutics’ Zynlonta, Antibody-Drug Conjugates (ADC) in RR DLBCL
ASH 2022: Roche’s Polivy vs ADC Therapeutics’ Zynlonta, Antibody-Drug Conjugates (ADC) in R/R DLBCL

Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experimentations and their upshots are always brought to us through various platforms, the Ameri...

Find More

More Views & Analysis

DLBCL ASH 2022
ASH 2022: Yescarta emerging as the CAR-T leader in DLBCL; Failure of Kymriah in early lines of DLBCL

CAR T-cell therapy is a type of immunotherapy that uses your body's white blood cells to fight your lymphoma. It uses a particular kind of white blood cell known as T lymphocytes or T cells. An essential part of CART therapies is lymphodepleting conditioning, which is administered to the patient before infusion of ...

Find More

Recurrent Clostridium Difficile Infection (rCDI) Market Outlook, Emerging Therapies, and Epidemiology
Evaluating the Potential of Emerging Therapies for Recurrent Clostridium Difficile Infection (rCDI)

Clostridium difficile Infection (CDI), one of the most common nosocomial and community-acquired infections globally, is a major public health challenge. The Clostridium difficile bacteria are a toxin-producing pathogen that produces two types of toxins: toxin A (an enterotoxin) and toxin B (a cytotoxin). This toxin...

Find More

myotonic-dystrophy-treatment-market-assessment
Myotonic Dystrophy Treatment: In Search of Effective Weaponry to Kick Out Toxic RNAs Weakening Muscles

Myotonic dystrophy (DM), known as "the most variable of all diseases found in medicine," is a multi-systemic genetic disorder that is the most common form of adult-onset muscular dystrophy. myotonic dystrophy is the only type of muscular dystrophy that affects cognition and brain function, in addition to the heart,...

Find More

chronic-smell-and-flavour-loss-treatment-market-outlook
Chronic Smell and Flavor Loss Treatment Market Garners Attention amid the Pandemic Chaos

Smell and taste disorders affect an individual’s choice of following a safe and healthy diet. Besides, they also impact food-related behaviors, like enjoying a meal. These disorders impair the ability to sense warning odors in foods and the environment and hinder the quality of life (QoL) related to social interact...

Find More

Rheumatoid Arthritis Key Trends and Emerging Therapies
Which Key Player Holds the Potential to Corner the Rheumatoid Arthritis Therapeutics Market?

Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive and destructive polyarthritis and affects approximately 1% of the population. It is characterized by chronic pain and joint destruction that usually progress from distal to more proximal joints.  DelveInsight ...

Find More

pd-and-pd-l1-inhibitors-in-cancer-treatment
PD-1 and PD-L1 Inhibitors: Will They Dominate Over Conventional Cancer Therapies?

The development of tumor therapy in cancer immunotherapy has been aided by programmed death receptor-1 and programmed death protein ligand inhibitors. Since its discovery in 1990, the programmed cell death protein 1 receptor (PD-1) receptor has been known to negatively regulate T-cell mediated immune response via i...

Find More

Alzheimer's disease is an irreversible, progressive disorder of the brain that progressively destroy.....

Find More

Fragile X Syndrome is a syndrome, which results in intellectual disabilities as well as affects the .....

Find More

Raynaud’s phenomenon (RP) is a condition that results in discoloration of fingers or toes caused b.....

Find More

There are about 200 different types of cancer, making it one of the most diverse types of indication.....

Find More

The gene therapy in rare diseases market has drastically changed recently due to scientific advancem.....

Find More

Primary Progressive Aphasia (PPA) is a rare neurological disorder that results from the damages to t.....

Find More